Nature Communications (Jun 2020)
Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours
- João M. Fernandes Neto,
- Ernest Nadal,
- Evert Bosdriesz,
- Salo N. Ooft,
- Lourdes Farre,
- Chelsea McLean,
- Sjoerd Klarenbeek,
- Anouk Jurgens,
- Hannes Hagen,
- Liqin Wang,
- Enriqueta Felip,
- Alex Martinez-Marti,
- August Vidal,
- Emile Voest,
- Lodewyk F. A. Wessels,
- Olaf van Tellingen,
- Alberto Villanueva,
- René Bernards
Affiliations
- João M. Fernandes Neto
- Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121
- Ernest Nadal
- Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L’Hospitalet del Llobregat
- Evert Bosdriesz
- Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121
- Salo N. Ooft
- Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute
- Lourdes Farre
- Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L’Hospitalet del Llobregat
- Chelsea McLean
- Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute
- Sjoerd Klarenbeek
- Experimental Animal Pathology, The Netherlands Cancer Institute
- Anouk Jurgens
- Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121
- Hannes Hagen
- Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121
- Liqin Wang
- Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121
- Enriqueta Felip
- Department of Medical Oncology, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)
- Alex Martinez-Marti
- Department of Medical Oncology, Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology (VHIO)
- August Vidal
- Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L’Hospitalet del Llobregat
- Emile Voest
- Division of Molecular Oncology and Immunology, The Netherlands Cancer Institute
- Lodewyk F. A. Wessels
- Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121
- Olaf van Tellingen
- Division of Clinical Pharmacology, The Netherlands Cancer Institute
- Alberto Villanueva
- Group of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L’Hospitalet del Llobregat
- René Bernards
- Division of Molecular Carcinogenesis and Oncode Institute. The Netherlands Cancer Institute, Plesmanlaan 121
- DOI
- https://doi.org/10.1038/s41467-020-16952-9
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 9
Abstract
A drug used at the maximum tolerated dose can exert a strong selective pressure on cancer cells leading to resistance. In this study, the authors demonstrate the efficacy of using low dose of multiple drugs for preventing and treating resistance to EGFR tyrosine kinase inhibitors in NSCLC cells.
